<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35035">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758120</url>
  </required_header>
  <id_info>
    <org_study_id>GGH2012-36</org_study_id>
    <secondary_id>GGH2012-36</secondary_id>
    <nct_id>NCT01758120</nct_id>
  </id_info>
  <brief_title>Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy</brief_title>
  <acronym>TOPplus-IgAN</acronym>
  <official_title>A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone
      alone in patients with advanced-stage IgA nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>the changes of kidney function</measure>
    <time_frame>3,6 ,12, 24 and 36 months or more after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the changes of glomerular filtration rate (GFR) or a combination of reaching end-stage renal disease (ESRD) or doubling of serum Creatinine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the changes of proteinuria</measure>
    <time_frame>3,6 ,12, 24 and 36 months or more after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>1,3,6 ,12, 24 and 36 months or more after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of Participants with Adverse Events; adverse events include hair loss, vomiting, diarrhea, jaundice, leukopenia, anemia, thrombocytopenia, infections, allergic reactions and hemorrhagic cystitis.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>prednisone plus cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prednisone alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prednisone alone: prednisone(0.5mg/kg/day*6 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone plus cyclophosphamide</intervention_name>
    <description>prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)</description>
    <arm_group_label>prednisone plus cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone alone</intervention_name>
    <description>prednisone alone: prednisone(0.5mg/kg/day*6 months)</description>
    <arm_group_label>prednisone alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy-proven primary IgA nephropathy;

          -  18-70 years old;

          -  serum Creatinine:1.5-3.0mg/dl;

          -  with a written consent from participants to receive prednisone and/or
             cyclophosphamide

        Exclusion Criteria:

          -  diabetes;

          -  contraindications for the treatment of prednisone and/or cyclophosphamide;

          -  any treatment with steroids or immunosuppressive drugs prior to this study;

          -  acute deterioration of renal function(including those of glomerular origin)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wei shi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Shi, MD, PhD</last_name>
    <phone>(86-20)83850849</phone>
    <email>weishi_gz@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Zhang, MD PhD</last_name>
      <phone>+86-13925056339</phone>
      <email>zhangbinyes@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhongling Feng, Master</last_name>
      <phone>+86-13828431229</phone>
      <email>13828431229@139.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bin Zhang, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>zhongling Feng, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianteng Xie, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huaban Liang, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lixia Xu, MD  PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 27, 2013</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong General Hospital</investigator_affiliation>
    <investigator_full_name>Wei Shi</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>IgA nephropathy</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>prednisone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
